GSK and Theravance Announce Regulatory Submissions for FF/VI in the US and … – MarketWatch (press release)

GSK and Theravance Announce Regulatory Submissions for FF/VI in the US and
MarketWatch (press release)
Asthma (100/25mcg and 200/25mcg): The regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate. COPD (100/25mcg): The
GSK, Theravance unveil Regulatory Submissions for FF/VI in US, EuropeRTT News
GSK files key new lung drug for regulatory approvalWHTC

all 7 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.